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Down syndrome (DS) results from a trisomy of chromosome 21, which causes immune dysregulation that leads to hyperactivation
of interferon and Janus kinase (JAK) signaling. This results in complex medical abnormalities in the immune system and an
increase in autoimmune and autoinflammatory conditions such as down syndrome-associated arthritis (DA). DA is an aggressive,
destructive, inflammatory arthritis that is easily misdiagnosed and difficult to treat. Treatment commonly includes immunosuppressive therapy, but these are often associated with adverse effects and ineffectiveness. This case report outlines a 6-year-old
male with DA that was successfully treated with the JAK inhibitor tofacitinib. Due to the aggressive nature of DA and poor
response to many immunosuppressive therapies, this case report was created to increase awareness of JAK inhibition as an
effective, well-tolerated treatment for DA.

1. Introduction
Down syndrome (DS) is one of the most common birth
defects in the United States [1] and the most common genomic disorder that results from a trisomy of human
chromosome 21 [2]. The trisomy 21 results in an increased
prevalence of hypothyroidism, congenital heart disease,
hematologic disorders, and autoimmune disease such as
celiac disease, diabetes mellitus, and down syndrome-associated arthritis (DA) [3]. It has been established that there
is immune dysregulation in those with DS that contributes to
elevated levels of the tumor necrosis factor (TNF) and interferon (IFN) [4] as the trisomy 21 causes hyperactivation of
IFN and Janus kinase (JAK) signaling [5, 6] and may be
responsible for the cause of DA. Most children with DA
present with polyarticular (five or more joints with arthritis
at presentation), rheumatoid factor (RF), and antinuclear
antibody (ANA) negative disease that is aggressive with bone
and joint damage at presentation. There is also a long delay
in diagnosis due to lack of screening guidance and misdiagnosis due to common mechanical issues seen in those with

DS such as pes planus, hypermobility, and hypotonia [3].
Once diagnosed, and despite aggressive immunosuppressive
therapy, the disease burden remains high, and therapeutic
challenges are common due to an increase in adverse effects
and ineffectiveness of therapy [7]. Synthetic and biologic
disease modifying antirheumatic drugs (DMARDs) have not
been as successful as a therapeutic option for DA compared
to other forms of arthritis due to poor disease control and
adverse effects [3]. With the hyperactivation of IFN and JAK
signaling seen in DS, JAK inhibition is an appealing option
for disease control. This report describes the first reported
case of a pediatric patient with DA who was successfully
treated to clinically inactive disease with the JAK inhibitor
tofacitinib.

2. Case Presentation
A 6-year-old male with trisomy 21 (meiotic nondisjunction),
hypothyroidism (with negative thyroid peroxidase and
thyroid globulin antibodies), and a history of frequent
bacterial, viral, and topical fungal infections with
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hypogammaglobulinemia requiring IVIg was seen in the
rheumatology clinic in July of 2017 for a 12-month history of
bilateral foot and ankle pain. There was right ankle swelling
and limitation that had been present for the previous three
months, which was thought to be correlated to an increase in
activity over that time frame with starting school and a new
dance class. The right ankle swelling ﬂuctuated in severity
but never completely resolved, and there were 20 minutes of
morning stiﬀness daily. The swelling and limitation did
improve with ibuprofen (10 mg/kg every 6 hours as needed)
but never resolved. On physical exam, the patient was noted
to have swelling and limitation of bilateral ankles with
antalgic gait along with generalized joint hypermobility
(Beighton score of 8/9) and bilateral pes planus. His initial
laboratory evaluation revealed a normal C-reactive protein
(CRP; <0.5 mg/dL), erythrocyte sedimentation rate (ESR;
8 mm/h), complete blood count (without any cytosis or
cytopenia), negative ANA, RF, and human leukocyte antigen
B-27. He had low immunoglobulin G (602 mg/dL), immunoglobulin M (44 mg/dL), and normal immunoglobulin
A (81 mg/dL). An ultrasound of bilateral ankles and feet
showed the ﬂuid surrounding the bilateral extensor digitorum longus, left peroneal brevis and longus tendons, and
left extensor hallucis longus tendon consistent with tenosynovitis. He was started on naproxen (10 mg/kg twice
daily), and after eight weeks, he showed minimal improvement in pain, swelling, and limitation. The family was
hesitant to start immunosuppressive therapy due to his
history of recurrent infections with hypogammaglobulinemia, and so he was switched to meloxicam (0.25 mg/kg
daily). After an eight-week course, there was no improvement in ankle and foot pain and swelling, and he continued
to have antalgic gait. His morning stiﬀness persisted and
increased to 30 minutes daily. He also developed swelling
and discomfort in his bilateral second and third metacarpophalangeal joints. His family remained hesitant about
immunosuppression but was interested in additional therapy, and hydroxychloroquine (3.5 mg/kg daily) was added.
The combination of meloxicam and hydroxychloroquine did
result in mild improvement in ankle, foot, and hand swelling
and limitation over the next ﬁve months; however, none of
the symptoms resolved. There were plans to start IV abatacept for continued evidence of active arthritis; however,
the patient developed seizures and regression with oral
intake, eating, toileting, and weight loss, and the family
wanted to prioritize evaluation and treatment of neurodevelopmental and behavioral issues, so the patient was
continued on the combination of meloxicam and hydroxychloroquine. The medications were inconsistently used due
to the other health issues related to DS until April 2020 when
he developed an upper respiratory infection with fever and
had worsened joint pain, limitation, and swelling in bilateral
ankles, feet, and metacarpophalangeal joints. In addition, he
developed swelling and limitation in the bilateral knees.
After resolution of the febrile illness he continued with pain,
swelling, limitation, and antalgic gait. He did not want to
engage in activities he usually enjoyed and would avoid
physical activities as well. After his febrile illness resolved,
laboratory tests showed normal platelets (429 × 103/mcL)
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and hemoglobin (13.3 gm/dL) with low white blood cells
(4.1 × 103/mcL), elevated ESR (18 mm/h), and normal CRP
(<0.5 mg/dL). With the increase in inﬂammatory arthritis
symptoms and impact on quality of life, the family decided
they were ready to escalate to immunosuppressive therapy.
A discussion of risks and beneﬁts was undertaken to outline
additional therapy options. We decided to avoid corticosteroids due to the common adverse eﬀects such as weight
gain that is commonly experienced in children with DS [8].
We also avoided synthetic DMARDs such as methotrexate
due to the increased intolerance and adverse eﬀects experienced in children with DS [9]. In addition, evidence shows
that many patients with DA have poor response to biologic
DMARDs such as anti-TNF inhibitors [7], so we looked for
another option for treatment. Since trisomy 21 causes elevated levels of IFN through JAK signaling, a JAK inhibitor
such as tofacitinib was determined to be an appealing
possible therapeutic option. In addition, the family was
worried about administration of injectable synthetic and
biologic DMARDs, which can be challenging in the pediatric
population. Furthermore, the patient was under investigation for autism due to behavioral changes and regression,
and the family felt an injectable therapy would be diﬃcult to
administer regularly. At the time (April 2020), no JAK inhibitor was approved by the United States Food and Drug
Administration (FDA) for arthritis in children, but it was
under investigation in clinical trials and was approved for
use in adults with inﬂammatory arthritis. JAK inhibition was
determined to have good potential for disease control, and so
tofacitinib was initiated at 2.5 mg orally, twice daily. There
was a rapid improvement in joint swelling, limitation, and
stiﬀness. There was no more morning stiﬀness or antalgic
gait. The patient was noted to be more active with improved
mood, and there was complete resolution of arthritis two
months after initiation of tofacitinib. The laboratory tests
(CRP and ESR) continued to be normal, and there were no
adverse eﬀects or serious infections reported since initiation
approximately 28 months ago.

3. Discussion
Down syndrome-associated arthritis (DA) is an aggressive,
destructive, inﬂammatory arthritis that has long delay in
time from symptom onset to diagnosis that can be up to
three years due to being underrecognized [9]. In addition,
those with DS commonly have hypotonia, hypermobility,
pes planus, and autism, which may mislead providers and
further delay diagnosis. Patients with DA commonly present
with bone and joint damage at presentation; however, the
patient reported here was diagnosed earlier than usual as the
down syndrome clinic at our institution has a brief musculoskeletal screen given to all patients seen in the DS clinic,
which includes focused questions about musculoskeletal
pain and limitation with positive screens that trigger additional evaluation and referral as appropriate [10]. This does
provide support for regular musculoskeletal screening for
patients with DS as DA has a prevalence of 10 per 1000
patients [3]; however, the optimal timing and interval of
screening is unclear.
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Once diagnosed, the therapeutic approach to DA has been
similar to juvenile idiopathic arthritis (JIA) [11], which is the
most common rheumatic disease in childhood. JIA is an autoimmune disease that results in arthritis in children, and
studies have shown diﬀerences in clinical presentation and
pathogenesis between DA and JIA. A study that evaluated the
adaptive immune system of individuals with DA and JIA found
that those with DA had expansion of IgM-only memory B cells
and decreased number of transitional B cells. It was also noted
that those with DA have increased proinﬂammatory cytokines
TNF and INF compared to those with JIA. It is thought that the
proinﬂammatory cytokine response is associated with increased T cell plasticity in those with DA [12]. There have also
been ﬁndings to suggest that the synovial tissue inﬂammation is
diﬀerent between those with DA and JIA with increased inﬁltration of T and B cells in the inﬂamed synovium in DA [12].
The immune dysregulation in DA is likely in part caused by the
four IFN receptors encoded on chromosome 21, which leads to
hypersensitivity of IFN ligands, increased JAK signaling, and
increase in proinﬂammatory autoimmune and autoinﬂammatory disease [5, 6, 13]. Evidence continues to build
that shows a connection among increased IFN, JAK signaling,
and inﬂammatory disease in those with DS. In September 2020,
the JAK inhibitor tofacitinib was approved by the FDA for
treatment of polyarticular JIA in children of 2 years of age and
older. This approval may make it easier for those with DA to
obtain this medication now, as some view DA and JIA as the
same disease [11], despite growing evidence to suggest otherwise [3]. In addition, JAK inhibition has also been used to
successfully treat psoriatic arthritis in an adult with DS [14]
with rapid improvement in skin and joint disease and no
adverse eﬀects. This further supports JAK inhibition for inﬂammatory conditions seen in DS.
DA is an aggressive, destructive, inﬂammatory joint
disease in those with DS that is poorly understood; however,
as awareness of DA improves and as more individuals with
DS are diagnosed, we will need better therapies and therapeutic approaches that are tailored to those with DA. The
current therapeutic options for DA, which have been borrowed from JIA, come with more adverse eﬀects and less
eﬀectiveness; however, JAK inhibition may become a preferred option for those with DA as it is oral medication, has
proven eﬀective for arthritis treatment, and targets the
immune dysregulation seen in those with DS.

Data Availability
All data used to support the ﬁndings of this study are
available upon request to the corresponding author.

Conflicts of Interest
The authors declare that they have no conﬂicts of interest.

Authors’ Contributions
JJ developed conception, drafting, and ﬁnal version of the
whole manuscript. All authors read and approved the ﬁnal
manuscript.

3

References
[1] G. de Graaf, F. Buckley, and B. G. Skotko, “Estimates of the live
births, natural losses, and elective terminations with Down
syndrome in the United States,” American Journal of Medical
Genetics, Part A, vol. 167, no. 4, pp. 756–767, Apr 2015.
[2] S. E. Antonarakis, B. G. Skotko, M. S. Raﬁi et al., “Down
syndrome,” Nature Reviews Disease Primers, vol. 6, no. 1, p. 9,
2020, https://pubmed.ncbi.nlm.nih.gov/32029743/.
[3] J. T. Jones, J. Kitchen, and N. Talib, “Down syndrome-associated arthritis (DA): diagnostic and management challenges,” Pediatric Health, Medicine and Therapeutics, vol. 13,
pp. 53–62, 2022.
[4] M. N. Rostami, M. Douraghi, A. M. Mohammadi, and
B. Nikmanesh, “Altered serum pro-inﬂammatory cytokines in
children with Down’s syndrome,” European Cytokine Network, vol. 23, no. 2, pp. 64–67, 2012.
[5] K. D. Sullivan, H. C. Lewis, A. A. Hill et al., “Trisomy 21
consistently activates the interferon response,” Elife, vol. 5,
Article ID e16220, 2016.
[6] K. A. Waugh, P. Araya, A. Pandey et al., “Mass cytometry
reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome,” Cell
Reports, vol. 29, no. 7, pp. 1893–1908, 2019.
[7] J. T. Jones, C. Smith, M. L. Becker, D. Lovell, and
C. R. Investigators, “The Down syndrome-associated arthritis
cohort in the new childhood arthritis and rheumatology research alliance (CARRA) registry: clinical characteristics,
treatment and outcomes,” Arthritis Care & Research, vol. 73,
2020.
[8] J. T. Jones, C. Smith, and N. Talib, “Assessment of Down
syndrome-associated arthritis: a survey of Down syndrome
clinic providers,” Global Pediatric Health, vol. 8, 2021.
[9] J. T. Jones, N. Talib, D. Lovell, and M. L. Becker, “Clinical
features and treatment of Down syndrome arthropathy: experience from two US tertiary hospitals,” Pediatric Drugs,
vol. 21, no. 1, pp. 33–39, 2019.
[10] J. T. Jones, C. Smith, and N. Talib, “Brief musculoskeletal
screen and patient education for Down syndrome-associated
arthritis,” Global Pediatric Health, vol. 8, 2021.
[11] A. Nicek, N. Talib, D. Lovell, C. Smith, M. L. Becker, and
J. T. Jones, “Assessment and treatment of Down syndromeassociated arthritis: a survey of pediatric rheumatologists,”
Pediatric Rheumatology, vol. 18, no. 1, p. 57, 2020.
[12] C. Foley, A. Floudas, M. Canavan, M. Biniecka et al., Increased
T cell plasticity with dysregulation of follicular helper T,
peripheral helper T, and treg cell responses in children with
juvenile idiopathic arthritis and Down syndrome-associated
arthritis,” Arthritis & Rheumatology, vol. 72, no. 4,
pp. 677–686, 2019.
[13] R. K. Powers, R. Culp-Hill, M. P. Ludwig et al., “Trisomy 21
activates the kynurenine pathway via increased dosage of
interferon receptors,” Nature Communications, vol. 10, no. 1,
2019.
[14] A. T. Pham, A. L. Rachubinski, B. Enriquez-Estrada,
K. Worek, M. Griﬃth, and J. M. Espinosa, “JAK inhibition for
treatment of psoriatic arthritis in Down syndrome,” Rheumatology, vol. 60, no. 9, pp. e309–e311, 1 2021.

